Drug Trial Radar · NCT07433387
Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jan 29, 2026
Primary completion
Jul 10, 2026
Study completion Sep 25, 2026
Sponsor
- Lead sponsor
- Shanxi Kangbao Biological Product Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Institute of Pathogen Biology, Beijing, China
- First posted
- Feb 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 for Injection in Antiretroviral Therapy-Naive HIV-Infected Individuals
Conditions
- HIV
Interventions
LP-98 20 mgDrug
The study plans to enroll a total of 30 subjects, with 10 subjects in each cohort. Enrolled subjects will receive LP-98 treatment at doses of 20 mg, 40 mg, or 80 mg according to their assigned cohort. The drug will be administered via subcutaneous injection, with an interval of 14 days between doses, for a total of 4 doses.
LP-98 40 mgDrug
LP-98 40 mg
LP-98 80 mgDrug
LP-98 80 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma HIV RNA levels (log10 copies/mL) and changes from baselineTime frame: Within 71 days after the first administration.
- Proportion of subjects with plasma HIV RNA < 50 copies/mLTime frame: Within 71 days after the first administration.
- Proportion of subjects with plasma HIV RNA < 200 copies/mLTime frame: Within 71 days after the first administration.
- Absolute CD4+ T lymphocyte count and change from baselineTime frame: Within 71 days after the first administration.
- CD4+/CD8+ T lymphocyte ratio and change from baselineTime frame: Within 71 days after the first administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Second People's Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.